111, Inc. revenue

111, Inc.'s revenue was $1.75bn in fiscal 2025, down 12.7% on the year before. Since fiscal 2016 ($132m) it has grown at a compound 33.3% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

111, Inc.: revenue history, annual
Fiscal year	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	132	142	271	572	1,189	1,926	2,013	2,113	2,002	1,747
Growth on the year before	—	+7.9%	+90.5%	+111.5%	+107.7%	+62.0%	+4.5%	+5.0%	−5.3%	−12.7%
Gross profit	11	12	16	24	53	96	125	120	115	101
Gross margin	8.5%	8.4%	5.8%	4.2%	4.5%	5.0%	6.2%	5.7%	5.8%	5.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Health Care Distributors: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
111, Inc.	$1.75bn	-12.7%	—
Henry Schein	$13.60bn	6.5%	2.6%
Cosmos Health Inc.	$73.7m	33.8%	14.8%
Cellyan Biotechnology Co., Ltd	$13.4m	-33.9%	—
Cencora	$332.77bn	5.1%	9.4%
McKesson	$410.98bn	8.8%	13.1%

Compare with peers

Head to head: HSIC vs YI COSM vs YI HKPD vs YI COR vs YI

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from 111, Inc.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to 111, Inc.